This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Utilising its innovative technology Arecor has developed a series of proprietary stable aqueous rapid-acting, ultra-concentrated insulin (up to 1,000 U/mL) formulations, which will not only offer a vastly superior mealtime insulin product for people requiring >200 U/day, but is also a critical step towards the advancement of the miniaturisation of delivery devices.